A Live Attenuated Dengue Virus Vaccine (Dengvaxia®) is Suppressed in Individuals With Immunity to Serotype 4
The Journal of Infectious Diseases · 2026-10-28
DOI: 10.1093/infdis/jiag522 ↗Abstract
Abstract Background Dengvaxia® was the first live attenuated tetravalent dengue virus (DENV) vaccine to be tested and approved for use in people. While Dengvaxia® was designed to be tetravalent, in humans, the vaccine performed like a monovalent DENV4 vaccine because the DENV4 vaccine virus replicated better than other vaccine serotypes. Dengvaxia® was safe and efficacious in children who were DENV-immune at baseline (BL) and contraindicated for use in DENV-naive children. Methods When Dengvaxia® was rolled out as a pediatric vaccine in the Philippines in 2016, we established a prospective cohort to assess vaccine performance by BL dengue serostatus. Here, we report on how BL monotypic immunity to each serotype (reflecting one past DENV infection) impacted Dengvaxia® responses. Results We observed that in children with BL immunity to DENV1, 2, or 3, the vaccine stimulated a secondary serotype cross-neutralizing Ab response, which likely explains the overall favorable performance of the vaccine in seropositive children enrolled in phase 3 trials. We observed a high frequency (61%) of vaccine suppression among DENV4 monotypic immune children. Conclusions Our results confirm the replication dominance of the DENV4 vaccine component in Dengvaxia® and directly implicate pre-existing DENV4 immunity in the suppression of the vaccine. Our results have broader implications for evaluating the performance of other DENV vaccines in seropositive individuals.
EUVIMED